Results 181 to 190 of about 4,706 (212)

Optimising Paediatric HIV Treatment: Recent Developments and Future Directions. [PDF]

Paediatr Drugs
Kamphuis AEM, Bamford A, Tagarro A, Cressey TR, Bekker A, Amuge P, Mujuru HA, Ndongo FA, Diack A, Compagnucci A, Lallemant M, Colbers A, Turkova A.   +12 more
europepmc   +1 more source

Leveraging existing market incentives to increase HIV pre-exposure prophylaxis access in the United States. [PDF]

J Int AIDS Soc
Ratevosian J, Piselli C, Sullivan P, Nelson LE.   +3 more
europepmc   +1 more source

Lenacapavir: Playing the Long Game in the New Era of Antiretrovirals. [PDF]

Clin Pharmacol Ther
Neverette NC, Dumond JB, McMahon DK, Devanathan AS.   +3 more
europepmc   +1 more source

Frontline evaluation: Atezolizumab-bevacizumab versus lenvatinib for BCLC stage B hepatocellular carcinoma exceeding the up-to-seven criteria. [PDF]

Cancer Med
Kimura M, Nishikawa K, Imamura J, Kimura K.   +3 more
europepmc   +1 more source

Safety evaluation of lenvatinib treatment after atezolizumab plus bevacizumab therapy for patients with unresectable liver cancer: A comparison of lenvatinib as 1st‑ or 2nd‑line treatment. [PDF]

Oncol Lett
Kimura M, Yamada S, Go M, Yasuda S, Toyoda H, Usami E.   +5 more
europepmc   +1 more source

Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review). [PDF]

Am J Cancer Res
Ye G, Ye M, Jin X.
europepmc   +1 more source